



AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (currently amended): A compound represented by formula ~~(I)~~(IA-2-1):



wherein ring A represents a cyclic group;

ring B represents a dihydronaphthalene, indene, or 6,7-dihydro-5H-benzo[7]annulene
~~cyclic group~~ which may further have a substituent(s);

X represents -CH₂-, -(CH₂)₂-, -(CH₂)₃-, -(CH₂)₄-, -(CH₂)₅-, -(CH₂)₆-, -(CH₂)₇-, -(CH₂)₈-, -
O-, -CH₂-O-, -(CH₂)₂-O-, -(CH₂)₃-O-, -(CH₂)₄-O-, -(CH₂)₅-O-, -CH=CH-CH₂-O- or -
cyclopropylene-CH₂-O-, which each may be substituted, in which the right side of each group is
bound to ring B; a bond or a spacer having 1 to 8 atoms in its main chain in which one atom in
the spacer may be taken together with a substituent on ring B to form a ring group which may
have a substituent(s);

ring D¹ represents a nitrogen-containing heterocyclic group;

Y¹⁻³ represents methylene which may have a substituent(s), ethylene which may have a substituent(s), propylene which may have a substituent(s) or propenylene which may have a substituent(s);

R²⁷ represents a hydrogen atom, a halogen atom, or C1-4 alkyl which may be substituted with 1 to 3 halogen atoms;

t is 0 or an integer of 1 to 5;

R¹ represents a substituent;

n represents 1;

m is 0 or an integer of 1 to 7, and when m is 2 or more, plural R¹s are the same or different;

when X is -O- or -CH₂-O- and ring A is phenyl, m is an integer of 1 to 7,

~~Y represents a bond or a spacer having 1 to 10 atoms in its main chain in which one atom in the spacer may be taken together with a substituent on ring B to form a ring group which may have a substituent(s);~~

~~n represents 0 or 1, wherein when n is 0, m is 1 and R⁺ represents a hydrogen atom or a substituent, and when n is 1, m is 0 or an integer of 1 to 7 and R⁺ represents a substituent in which when m is 2 or more, plural R⁺s are the same or different,~~

~~a salt thereof, a solvate thereof or a prodrug thereof.~~

2 - 4. (canceled).

5. (currently amended): The compound according to claim 21, wherein ring A is a benzene, indane, indene or naphthalene ring.

6 - 15. (canceled).

16. (currently amended): The compound according to claim ~~15~~1, wherein ~~Y~~¹-Y¹⁻³ is -CH₂-, -(CH₂)₂-, ~~-(CH₂)₂-CO-, -CO-(CH₂)₂-~~ or -(CH₂)₃-, which each may be substituted.


17 - 18. (canceled).

19. (currently amended): The compound according to claim ~~2~~1, wherein the substituent represented by R¹ is a halogen atom, C1-20 alkyl which may be substituted, or C1-20 alkyloxy which may be substituted.

20. (currently amended): The compound according to claim 19, wherein the substituent represented by R¹ is fluoro, chloro, bromo, methyl, ethyl, propyl, butyl, trifluoromethyl or methoxy.


21. (canceled).

22. (currently amended): The compound according to claim ~~2~~1, which is a compound represented by ~~formula (I-S-3a)~~:



wherein X^S has the same meaning as X described in claim 1, in which X^S is not $(CH_2)_q$ - E^a ; R^{S0} , R^{S1} , R^{S2} , R^{S3} , R^{S4} , R^{S5} , R^{S6} , R^{S7} , R^{S8} , R^{S9} , R^{S10} and R^{S11} each independently represents a hydrogen atom, a halogen atom, or C1-4 alkyl which may be substituted with 1 to 3 halogen atoms; E^a , q and other symbols have the same meanings as described in any one of claims 1 and 2, or

formula (I-S-7a):



wherein R^{S0} , R^{S1} , R^{S2} , R^{S3} , R^{S4} , R^{S5} and R^{S6} each has the same meaning as described above; R^{S12} , R^{S13} , R^{S14} and R^{S15} each independently represents a hydrogen atom, a halogen atom, or C1-4 alkyl which may be substituted with 1 to 3 halogen atoms; and E^a , q and other symbols have the same meanings as described in any one of claims 1 and 2.

23 - 24. (canceled).

25. (currently amended): The compound according to claim 21, which is

(1) N-((2E)-3-[4-(3-phenylpropoxy)phenyl]prop-2-enyl)-β-alanine,

- (2) — ~~N-{{6-(3-phenylpropoxy)-2-naphthyl}methyl}-β-alanine,~~
- (3) — ~~1-{{6-(3-phenylpropoxy)-2-naphthyl}methyl}azetidine-3-carboxylic acid,~~
- (4) — ~~1-{{6-(3-phenylpropoxy)-2-naphthyl}methyl}piperidine-4-carboxylic acid,~~
- (5) — ~~N-{{(2E)-3-[2-methyl-4-(3-phenylpropoxy)phenyl]prop-2-enyl}-β-alanine,~~
- (6) — ~~1-{{(2E)-3-[4-(3-phenylpropoxy)phenyl]-2-propenyl}piperidine-4-carboxylic acid,~~
- (7) — ~~1-{{(2E)-3-[4-(3-phenylpropoxy)phenyl]-2-propenyl}azetidine-3-carboxylic acid,~~
- (8) — ~~N-{3-[4-(3-phenylpropoxy)phenyl]propyl}-β-alanine,~~
- (9) — ~~3-(((2E)-3-[4-(3-phenylpropyl)phenyl]-2-butenyl)amino)propanoic acid,~~
- (10) — ~~3-(((2E)-3-[4-(3-cyclohexylpropoxy)-2-methylphenyl]-2-propenyl)amino)propanoic acid,~~
- (11) 1-{{1-methyl-6-(4-phenylbutoxy)-3,4-dihydro-2-naphthalenyl}methyl}-3-azetidinecarboxylic acid,
- (12) — ~~N-{{1-(5-phenylpentyl)-1H-indol-5-yl}methyl}-β-alanine,~~
- (13) — ~~3-[4-[4-(3-phenylpropoxy)phenyl]-3,6-dihydropyridin-1(2H)-yl]propanoic acid,~~
- (14) 1-({6-[3-(4-chlorophenyl)propoxy]-1-methyl-3,4-dihydro-2-naphthalenyl}methyl)-3-azetidinecarboxylic acid, or
- (15) 1-({6-[3-(4-fluorophenyl)propoxy]-1-methyl-3,4-dihydro-2-naphthalenyl}methyl)-3-azetidinecarboxylic acid.

26. (canceled).

27. (currently amended): A pharmaceutical composition which comprises a compound represented by formula (IA-2-1) in claim 1, a salt thereof, ~~a solvate thereof~~ or a prodrug thereof.

28. (original): The pharmaceutical composition according to claim 27, which is an S1P receptor binding agent.

29. (original): The pharmaceutical composition according to claim 28, which is an EDG-6 binding agent which may have an ability to bind to EDG-1.

30. (original): The pharmaceutical composition according to claim 29, wherein the EDG-6 binding agent which may have an ability to bind to EDG-1 is an EDG-6 agonist which may have an agonistic activity against EDG-1.

31. (original): The pharmaceutical composition according to claim 27, which is an agent for preventing and/or treating a disease related to EDG-1 and/or EDG-6.

32. (original): The pharmaceutical composition according to claim 31, wherein the disease related to EDG-1 and/or EDG-6 is rejection in transplantation, autoimmune disease and/or allergic disease.

33. (original): The pharmaceutical composition according to claim 31, wherein the disease related to EDG-1 and/or EDG-6 is rejection in transplantation of kidney, liver, heart,

lung, dermal graft, cornea, bone, bone marrow cells and/or pancreatic islet cells, collagen disease, systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, psoriasis, inflammatory bowel disease, Crohn's disease, autoimmune diabetes, lung fibrosis, atopic dermatitis and/or asthma.

34. (original): The pharmaceutical composition according to claim 27, which is an immunosuppressant agent.

35. (original): The pharmaceutical composition according to claim 27, which is an agent causing lymphopenia.

36. (canceled).

37. (currently amended): A medicament comprising the compound represented by formula (IA-2-1) according to claim 1, a salt thereof, ~~a solvate thereof~~ or a prodrug thereof in combination with one or at least two selected from the group consisting of an antimetabolite, an alkylating agent, a T cell activation inhibitor, a calcineurin inhibitor, a proliferation signal inhibitor, a steroid, an immunosuppressant agent, an antibody used in immune suppression, an agent for treating rejection, an antibiotic, an antiviral agent and an antifungal agent.

38. (original): An immunosuppressant agent and/or an agent causing lymphopenia, which comprises a compound which has an ability to bind to EDG-6 and may have an ability to bind to EDG-1.

39. (original): The immunosuppressant agent and/or the agent causing lymphopenia according to claim 38, which is an agent for preventing and/or treating rejection in transplantation, autoimmune disease and/or allergic disease.

40. (withdrawn-currently amended): A method for ~~preventing and/or~~ treating a disease related to EDG-1 and/or EDG-6 in a mammal, which comprises administering to ~~a~~the mammal an effective amount of the compound represented by formula (IA-2-1) according to claim 1, a salt thereof, ~~a solvate thereof~~ or a prodrug thereof.

41. (withdrawn-currently amended): A method for immune suppression and/or lymphopenia in a mammal, which comprises administering to ~~a~~the mammal an effective amount of the compound represented by formula (IA-2-1) according to claim 1, a salt thereof, ~~a solvate thereof~~ or a prodrug thereof.

42-43. (canceled).